Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cipla, Stempeutics ink...

    Cipla, Stempeutics ink licensing deal for Stempeucel-DFU to treat diabetic foot ulcer

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-17T13:17:13+05:30  |  Updated On 17 Sept 2019 1:17 PM IST
    Cipla, Stempeutics ink licensing deal for Stempeucel-DFU to treat diabetic foot ulcer

    Under the agreement, Cipla will get exclusive marketing rights for five years in India for the diabetic foot ulcer (DFU) product. Stempeutics will manufacture and supply the product to the Indian company, it added.


    New Delhi: Biotech firm Stempeutics Research on Monday said it has signed an out-licensing deal with pharma major Cipla for novel stem cell product 'Stempeucel-DFU' for treating non-healing diabetic foot ulcer. The deal consists of upfront payment and various milestones-based payments, Stempeutics Research said in a statement.


    Under the agreement, Cipla will get exclusive marketing rights for five years in India for the diabetic foot ulcer (DFU) product. Stempeutics will manufacture and supply the product to the Indian company, it added.


    The company, however, did not provide any financial details of the agreement.


    The availability of the product in India is expected from the beginning of 2021, after undergoing the Phase 3 clinical trial here, which is expected to begin from October 2019, Stempeutics Research said.


    "We are pleased to partner with Stempeutics in bringing the next generation of biologics to address unmet medical needs in India. DFU is a serious condition that requires immediate treatment to re-establish a blood-flow to the affected area to prevent a leg from amputation," Cipla India Business Head Nikhil Chopra said.


    Stempeucel-DFU offers a novel treatment approach to the physicians in India to treat DFU and, will substantially improve the quality of life of thousands of patients suffering from this painful disease, he added.


    Read Also: Cipla, B J Wadia Hospital enter partnership to set up paediatric palliative care unit


    Commenting on the development, Stempeutics CEO BN Manohar said, "We are extremely happy to collaborate with Cipla in developing cell therapy product for non-healing DFU."


    Manipal Education and Medical Group (MEMG) Group firm Stempeutics is an advanced clinical stage a bio-tech company.


    Read Also: Manipal Group Stempeutics, Kemwell strike a deal worth Rs 95 crore for global commercialisation of Stempeucel

    biotechBN ManoharCiplacipla agreementCipla marketing rightDFUdiabetic foot ulcerManipal Education and Medical GroupmemgNikhil Choprapharmapharma companypharma newspharma news indiaStempeuticsStempeutics Research
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok